Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?

Braftovi shows a higher response rate in a triplet combination after adding Opdivo. Shifting focus towards microsatellite stable metastatic colorectal cancer (MSS CRC) patients

Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated durable responses in the earlier setting of Multiple Myeloma: Updated findings from the CARTITUDE-2 trial

Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients

Gilead in trouble waters as Trodelvy shows below par response in 3L+ HR+/HER2- Breast Cancer Setting

Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic Breast Cancer

Enhertu carving out a new space for itself in HER2 low patients. A major-label expansion is likely on the way

Yet another failure in treating Small-Cell Lung Cancer as Roche's much-anticipated anti-TIGIT immunotherapy fails in Phase III

Consistent Results Across All Sub-Groups Seen in the Newly Launched First in Class LAG-3 Combination Drug Opdualag

Encouraging results of nivolumab + bevacizumab + FOLFOXIRI in patients with RAS/BRAF mutations as a 1st Line treatment option

Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022

The PROs Further Support Durvalumab + Chemo in Becoming The New Standard of Care in 1st Line Advanced Biliary Tract Cancer

Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Standard of Care For Advanced Biliary Tract Cancers

With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For HER2+ive Biliary Tract Cancers

Daiichi’s novel HER3 ADC has Shown To Have a Spark in HER3 NSCLC, post success in the HER3 Breast Cancer Trial